The case for imaging in drug trials

Article

Considering how far medical technology has advanced, drug trials are amazingly primitive. The early testing looks at safety-whether an experimental drug makes healthy people sick, how many get sick, and how sick they get. Later testing looks at whether

Considering how far medical technology has advanced, drug trials are amazingly primitive. The early testing looks at safety-whether an experimental drug makes healthy people sick, how many get sick, and how sick they get. Later testing looks at whether diseased people get well, how many, and how much better they get.

When the trials are over, drug developers and their investors must wait, sometimes for months, to see if a statistical improvement was achieved. Aren't we far enough downstream in the development of imaging technology that the lack of a response by patients to an experimental drug could be seen long before that?

It seems reasonable to believe that signs of improvement-a shrinking tumor documented on volumetric CT or metabolic changes indicated by MR spectroscopy or PET-will be apparent in patients who live longer. Given all the talk about a future in which medical treatments are adjusted on the basis of imaging studies that monitor patient response, I find it inconceivable that these imaging technologies are not being widely used in the clinical trials that develop these drugs.

At least one company is promoting this idea. Kendle International provides biopharmaceutical companies with software that quantitates body areas affected by experimental therapies. It is compatible with a variety of imaging technologies.

For the most part, however, Kendle's services and even the capabilities readily available on mainstream imaging equipment are not being utilized widely. They should be. The number of new drugs submitted to the FDA for approval has dropped over the past five years, despite enormous excitement over new prospects and a flood of venture capital. Things have gotten so bad that the FDA is urging pharma to adopt new methods for assessing the clinical effect of experimental drugs. Among them is the use of imaging technologies to serve as tools for evaluating when and how drugs take effect.

The radiology community and pharma should jump on this opportunity to team up to conduct studies that correlate fundamental changes with clinical response to drugs. The research could be done as an adjunct to clinical trials already under way. If correlations emerge, drug companies would have easy and effective means for determining whether to continue developing particular drugs or spending their money on more promising alternatives.

The only way to find out is to try.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.